TY - JOUR
T1 - Plasma levels of soluble AβPPβ as a biomarker for Alzheimer's disease with dementia
AU - Alexopoulos, Panagiotis
AU - Thierjung, Nathalie
AU - Economou, Polychronis
AU - Werle, Lukas
AU - Buhl, Felix
AU - Kagerbauer, Simone
AU - Papanastasiou, Anastasios D.
AU - Grimmer, Timo
AU - Gourzis, Philippos
AU - Berthele, Achim
AU - Hemmer, Bernhard
AU - Kübler, Hubert
AU - Martin, Jan
AU - Politis, Antonios
AU - Perneczky, Robert
N1 - Funding Information:
Bernhard Hemmer was supported by grants from the German Federal Ministry for Education and Research (BMBF), grant no. 01GI1601D (Munich), SFB CRC 128 and EU project MultipleMS. Part of the samples were provided by the biobank of the Department of Neurology of Klinikum rechts der Isar as part of the Joined Biobank Munich in the framework of the German Biobank node.
Publisher Copyright:
© 2019 - IOS Press and the authors. All rights reserved.
PY - 2019
Y1 - 2019
N2 - Cost- and time-effective markers of Alzheimer's disease (AD), reliable and feasible at the population level are urgently needed. Soluble amyloid-β protein precursor β (sAβPPβ) in plasma has attracted scientific attention as a potential AD biomarker candidate. Here we report that plasma sAβPPβ levels in patients with AD dementia and typical for AD cerebrospinal fluid (CSF) biomarker profiles (N=33) are significantly lower (p<0.01) than those of cognitively healthy elderly individuals without AD (N=39), while CSF sAβPPβ levels did not differ between the studied groups. This provides further evidence for the potential of sAβPPβ in plasma as an AD biomarker candidate.
AB - Cost- and time-effective markers of Alzheimer's disease (AD), reliable and feasible at the population level are urgently needed. Soluble amyloid-β protein precursor β (sAβPPβ) in plasma has attracted scientific attention as a potential AD biomarker candidate. Here we report that plasma sAβPPβ levels in patients with AD dementia and typical for AD cerebrospinal fluid (CSF) biomarker profiles (N=33) are significantly lower (p<0.01) than those of cognitively healthy elderly individuals without AD (N=39), while CSF sAβPPβ levels did not differ between the studied groups. This provides further evidence for the potential of sAβPPβ in plasma as an AD biomarker candidate.
KW - Biomarker candidate
KW - NIA-AA research framework diagnostic criteria
KW - soluble amyloid-β protein precursor β
UR - http://www.scopus.com/inward/record.url?scp=85065675499&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85065675499&partnerID=8YFLogxK
U2 - 10.3233/JAD-181088
DO - 10.3233/JAD-181088
M3 - Article
C2 - 30909232
AN - SCOPUS:85065675499
SN - 1387-2877
VL - 69
SP - 83
EP - 90
JO - Journal of Alzheimer's Disease
JF - Journal of Alzheimer's Disease
IS - 1
ER -